Enzolytics Inc. (ENZC)
USD 0.0
(-16.67%)
USD 0.0
(-16.67%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.12 Million USD | 26.21% |
| 2022 | -2.88 Million USD | -107.28% |
| 2021 | -611.71 Thousand USD | 57.69% |
| 2020 | -3.28 Million USD | -409.2% |
| 2019 | 1.05 Million USD | 61.81% |
| 2018 | -1.68 Million USD | -242.77% |
| 2017 | 327.44 Thousand USD | -988.58% |
| 2016 | -45.29 Thousand USD | 99.1% |
| 2015 | -5.02 Million USD | 0.0% |
| 2010 | -7.43 Million USD | -567.48% |
| 2009 | -922.11 Thousand USD | -137.39% |
| 2008 | -388.43 Thousand USD | -222.69% |
| 2007 | 316.6 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -167.2 Thousand USD | 0.0% |
| 2024 Q2 | 22.07 Thousand USD | 113.2% |
| 2023 Q3 | -2.24 Million USD | -80.38% |
| 2023 FY | - USD | 26.21% |
| 2023 Q1 | -412.78 Thousand USD | 55.17% |
| 2023 Q2 | -1.24 Million USD | -200.93% |
| 2022 Q2 | -769.98 Thousand USD | 6.74% |
| 2022 FY | - USD | -107.28% |
| 2022 Q4 | -920.76 Thousand USD | -153.39% |
| 2022 Q3 | -363.38 Thousand USD | 52.81% |
| 2022 Q1 | -825.66 Thousand USD | 0.0% |
| 2021 FY | - USD | 57.69% |
| 2021 Q1 | -559.86 Thousand USD | 38.8% |
| 2021 Q2 | -193.9 Thousand USD | 65.37% |
| 2021 Q3 | -370.21 Thousand USD | -90.93% |
| 2020 Q4 | -914.74 Thousand USD | 0.0% |
| 2020 FY | - USD | -409.2% |
| 2019 FY | - USD | 61.81% |
| 2018 FY | - USD | -242.77% |
| 2017 FY | - USD | -988.58% |
| 2016 FY | - USD | 99.1% |
| 2015 FY | - USD | 0.0% |
| 2011 Q1 | -244.46 Thousand USD | 94.01% |
| 2011 Q2 | -210.93 Thousand USD | 13.71% |
| 2010 Q1 | -510.58 Thousand USD | 15.91% |
| 2010 FY | - USD | -567.48% |
| 2010 Q4 | -4.08 Million USD | -562.0% |
| 2010 Q3 | -616.92 Thousand USD | -295.42% |
| 2010 Q2 | 315.69 Thousand USD | 161.83% |
| 2009 Q3 | -188.15 Thousand USD | -146.04% |
| 2009 Q1 | -50.3 Thousand USD | 56.06% |
| 2009 Q2 | -76.47 Thousand USD | -52.01% |
| 2009 Q4 | -607.17 Thousand USD | -222.69% |
| 2009 FY | - USD | -137.39% |
| 2008 Q4 | -114.49 Thousand USD | 27.8% |
| 2008 Q2 | -18.1 Thousand USD | -2.84% |
| 2008 FY | - USD | -222.69% |
| 2008 Q3 | -158.57 Thousand USD | -776.13% |
| 2008 Q1 | -17.6 Thousand USD | 32.55% |
| 2007 Q3 | -1561.00 USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | -26.09 Thousand USD | -1571.68% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 97.013% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 64.209% |
| SQZ Biotechnologies Company | -64.14 Million USD | 96.692% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 87.783% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 102.257% |
| Mesoblast Limited | -62.38 Million USD | 96.599% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -38.149% |
| Genus plc | 73.7 Million USD | 102.879% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 67.904% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 40.174% |
| Marizyme, Inc. | -34.28 Million USD | 93.81% |
| ContraFect Corporation | -64.99 Million USD | 96.735% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 75.809% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 53.117% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -51.378% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 19.755% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 8.684% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -309.622% |
| Accustem Sciences Inc. | -3.74 Million USD | 43.358% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 95.6% |
| EV Biologics, Inc. | -1.26 Million USD | -67.467% |
| Q BioMed Inc. | -617.62 Thousand USD | -243.577% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 159.407% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -235.549% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 7.111% |
| Biomind Labs Inc. | -1.03 Million USD | -105.116% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 121.485% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 70.368% |
| Skye Bioscience, Inc. | -13.54 Million USD | 84.336% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -42.666% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -8388.116% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 45.369% |
| IMV Inc. | -35.52 Million USD | 94.026% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 86.628% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 15.185% |
| GB Sciences, Inc. | -1.41 Million USD | -49.451% |
| Alpha Cognition Inc. | -9.7 Million USD | 78.136% |
| HST Global, Inc. | -5303.00 USD | -39915.633% |
| CSL Limited | 4.78 Billion USD | 100.044% |
| Halberd Corporation | -74.27 Thousand USD | -2756.836% |
| Resverlogix Corp. | -11.74 Million USD | 81.928% |
| Affymax, Inc. | -14.29 Million USD | 85.155% |
| SYBLEU INC | -141.57 Thousand USD | -1398.915% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 30.721% |
| argenx SE | -216.02 Million USD | 99.018% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 96.165% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 274.366% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -41.572% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 660.133% |
| AVAX Technologies, Inc. | -6.11 Million USD | 65.285% |
| Zenith Capital Corp. | -8.6 Million USD | 75.342% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.147% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -12080.868% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 13.261% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1105.531% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 94.646% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 26.632% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -102.81% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 31659.027% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -21.259% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -10.47% |
| BioStem Technologies, Inc. | -7.55 Million USD | 71.907% |
| ONE Bio Corp. | 13.61 Million USD | 115.588% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1071.822% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -3.161% |
| Agentix Corp. | -1.37 Million USD | -54.694% |
| LadRx Corporation | 412.28 Thousand USD | 614.702% |
| Cell Source, Inc. | -4.27 Million USD | 50.333% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -477.862% |
| Regen BioPharma, Inc. | 1.46 Million USD | 244.754% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -126.483% |
| NovAccess Global Inc. | -1.03 Million USD | -105.067% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 123.967% |
| Itoco Inc. | -1.86 Million USD | -13.539% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -458.988% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -90.146% |
| Kadimastem Ltd | -2.62 Million USD | 19.142% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -787.321% |
| CytoDyn Inc. | -18.02 Million USD | 88.23% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -2585.127% |
| Mobile Lads Corp. | -2.24 Million USD | 5.316% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -17252.433% |
| Qrons Inc. | -40.08 Thousand USD | -5194.351% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -336.921% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 502.331% |
| Rebus Holdings, Inc. | -951 Thousand USD | -123.137% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -99.813% |
| International Stem Cell Corporation | 202 Thousand USD | 1150.509% |
| Bioxytran, Inc. | -3.82 Million USD | 44.452% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -3931.21% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 13.806% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 94.084% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -4615.62% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 22.497% |
| Neutra Corp. | -181.24 Thousand USD | -1070.794% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 89.474% |
| PureTech Health plc | -11.62 Million USD | 81.749% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 89.473% |
| IXICO plc | -707 Thousand USD | -200.146% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 72.387% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 95.611% |
| CSL Limited | 4.73 Billion USD | 100.045% |
| Cellectis S.A. | -92.63 Million USD | 97.709% |